NCT02229266View on ClinicalTrials.gov

Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 22, 2017

Study Completion Date

April 22, 2017

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

NK cells

DRUG

Cytarabine

1 cycle of consolidation chemotherapy with high-dose cytarabine

Trial Locations (3)

Unknown

Klinikum Bayreuth, Bayreuth

Klinikum Chemnitz, Chemnitz

Universitätsklinikum Dresden, Dresden

Sponsors
All Listed Sponsors
collaborator

German Research Foundation

OTHER

lead

Technische Universität Dresden

OTHER